Phase II clinical trial in thoracic oncology in a targeted population with a rare molecular alteration
Background
A Phase II clinical trial in thoracic oncology was conducted in a targeted population with a rare molecular alteration. The study aimed to evaluate a therapeutic approach in a setting characterised by specific selection criteria and particular challenges related to the care of patients with a targeted molecular abnormality.
Running this project required rigorous organisation to ensure patient follow-up, the quality of the data collected and compliance with the protocol requirements. Pharmaspecific supported the sponsor in the operational and regulatory activities needed for the study to run smoothly.
Challenges identified
The project presented several operational challenges:
- recruitment of patients with a specific molecular alteration, making subject identification particularly complex
- management of the known toxicities of the treatment, requiring close and responsive follow-up
- methodical coordination between investigator sites to ensure consistent protocol implementation in a demanding multicentre setting.
These factors required rigorous planning and smooth communication between all those involved in this Phase II clinical trial in thoracic oncology.
Pharmaspecific’s role
Pharmaspecific handled the regulatory submissions, coordinated clinical trial agreement management and provided monitoring in France, ensuring a fast study start-up and full compliance with GCP (Good Clinical Practice) standards. The team also supported investigator sites in implementing the protocol and proactively managing toxicities, further strengthening the quality of clinical follow-up.
Results
Key takeaways
Explore our clinical case studies
- Oncology
- Haematology
- Virology
- Rare diseases
- Cardiology
- Medical devices
Supporting a multicentre oncology study
Setting up patient expense management and coordinating investigator sites for an international study.
- Multicentre observational study on optimising the oncology care pathway.
- Phase II clinical trial (paediatric oncology) — CINV prevention
- Phase II clinical trial in thoracic oncology in a targeted population with a rare molecular alteration
- National real-world data (RWD) centralisation project in oncology
Strengthening monitoring for an international trial
A dedicated CRA team to ensure data quality across several countries
- Multicentre Phase III trial in patients with relapsed multiple myeloma
- International Phase III clinical trial comparing a new molecule combined with rituximab with standard treatment in lymphomas.
- Bioequivalence clinical study in haematology in around twenty patients, comparing a new generic with the reference molecule
Securing the launch of a vaccine trial
Coordinated regulatory submissions in 6 countries simultaneously
Facilitating recruitment for an orphan disease
A patient concierge service to reduce the burden on a geographically dispersed population
Preparing for a regulatory inspection with confidence
An independent GCP audit to anticipate deviations before inspection
Bringing an implantable device into MDR compliance
Comprehensive regulatory support, from strategy to submission
